Ireland
--:--IST
Active, not recruiting Not applicable

Medicsen Smartpatch: Safety & Performance (SOUNDD)

NCT07615959 · tracked via the Priya Life Science Spain tracker
Sponsor
Medicsensors S.L
Phase
Not applicable
Started
2026-01-20
Last updated
2026-05-29

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Medicsen SmartpatchSubcutaneous (SC) single dose

Medicsen Smartpatch: This intervention consists of administering the drug using the Medicsen Smartpatch, a non-invasive, needle-free drug delivery device that utilizes sonophoresis technology to enhance absorption through the skin.

Subcutaneous (SC) single dose: This intervention consists of administering the drug via standard subcutaneous injection using a pre-filled pen injector

Study summary

The goal of this clinical trial is to understand the efficacy of Medicsen's Smartpatch to deliver drugs through the skin in healthy volunteers. The main questions it aims to answer are:

* Is the administration with Medicsen Smartpatch safe for the patient?
* Can Medicsen's Smartpatch be used to effectively administer drugs to patients?

Researchers will compare administration with Medicsen's Smartpatch with the subcutaneous administration of the drug to see if the efficacy and safety are comparable

Participants will be asked to fill a tolerability survey after receiving each of the two interventions: Subcutaneous administration and Medicse's Smartpatch.

Blood samples will be taken at different timepoints to asses for efficacy of each treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Subjects must provide signed informed consent prior to participation in any study related procedures * Healthy Caucasian volunteers, any sex, aged between 18 to 55 years * Body Mass Index (BMI) between 18.5 and 30.0 kg/m2 * Ability and agreement to comply with the study requirements * Medical history and physical examination within normal limits. * No clinically relevant abnormalities in hematology, biochemistry, virology, or urine tests. * Participants who engage in sexual activity which could result in pregnancy for themselves or their partner(s) must agree to use highly effective methods of contraception during the clinical investigation. Exclusion Criteria: * Case history of hypersensitivity to medicinal products or any other allergic process that could interfere with study according to the investigator's judgement. * Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, dermatology, gastrointestinal distress, hypertension, or infectious acute processes that could interfere with study according to the investigator's judgement. * Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgement. * Administration of topic or systemic medication including medicinal plants within 14 days before the intervention. * Presence of skin disorders or lesions at the intended application site (e.g., eczema, psoriasis, infections, open wounds), which may interfere with drug absorption or increase risk of adverse effects. * Implanted electronic medical devices, such as pacemakers or neurostimulators, due to potential interference with ultrasonic energy. * Pregnant or breastfeeding women, due to lack of safety data for either the drug or the ultrasound application in this population. * Severe cognitive or motor impairment, where safe operation of the patch cannot be ensured, unless under continuous caregiver supervision.

Primary outcome measure(s)

  • Stage 1 - Device-related adverse events (adverse device effects; ADEs) — Periprocedural
    Primary Outcome Measure of Stage 1. Incidence and severity of ADEs is assesed, with special focus on those occurred at the site of administration and those leading to treatment interruption.
  • Stage 1 - Assessment of local tolerability through questionnaires and visual examination — Periprocedural
    Primary Outcome Measure of Stage 1. Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration are assesed through questionnaires. Dermatologist-evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) are assesed through visual examination.
  • Stage 2 - Area under the curve (AUC0-∞ and AUC0-t) — Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose
    Primary Outcome Measure of Stage 2
  • Stage 2 - Peak plasma concentration (Cmax) — Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose
    Primary Outcome Measure of Stage 2

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitario Ramon y Cajal Madrid Madrid
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07615959 on ClinicalTrials.gov ↗ ← All trials in Spain